| All Releases
|
|---|
 |
Cytori Receives Approval From FDA to Initiate U.S. Cardiac Cell Therapy Trial; Investigational Device Exemption (IDE) Approved for ATHENA
Jan 30, 2012
|
12.8 KB
|
| |
SAN DIEGO, CA -- (MARKET WIRE) -- 01/30/12 --
Cytori Therapeutics (NASDAQ: CYTX) has received an Investigational Device Exemption (IDE) approval from the U.S. FDA to begin the ATHENA trial. ATHENA will investigate the use of the Celution® System, an innovative medical device to prepare adipose-derived stem and regenerative cells (ADRCs) t...
|
|
|
Adipose Stem Cell Heart Attack Trial Data Published in Journal of the American College of Cardiology; Cytori's APOLLO Trial Demonstrated Safety & Feasibility and Improvements in Cardiac Function
Jan 24, 2012
|
15.1 KB
|
| |
SAN DIEGO, CA -- (MARKET WIRE) -- 01/24/12 --
Cytori Therapeutics (NASDAQ: CYTX) announced today the publication of previously reported six-month outcomes from APOLLO, the Company's European clinical trial evaluating adipose-derived stem and regenerative cells (ADRCs) in patients with acute myocardial infarction (heart attack or AMI), as Resea...
|
|
|
Cytori Announces Presentations at Biotech Showcase on Jan 9th and 10th
Jan 5, 2012
|
11.0 KB
|
| |
SAN DIEGO, CA -- (MARKET WIRE) -- 01/05/12 --
Cytori Therapeutics, Inc. (NASDAQ: CYTX) will webcast their corporate presentation at the Biotech Showcase at 4:00 PM PT on Monday, January 9 in San Francisco. The webcast may be accessed under "Webcasts" in the Investor Relations section of the Company's website, www.cytori.com. The webcast can be...
|
|
|
Cytori Completes IDE Filing for Chronic Myocardial Ischemia ATHENA Trial of the Celution® System
Dec 19, 2011
|
12.3 KB
|
| |
SAN DIEGO, CA -- (MARKETWIRE) -- 12/19/11 --
Cytori Therapeutics (NASDAQ: CYTX) filed its Investigational Device Exemption (IDE) application to begin a clinical trial of the Company's Celution® System for chronic myocardial ischemia (CMI).
ATHENA is a device-based safety and feasibility trial (Phase I/II) to investigate the use...
|
|
|
Cytori's Celution(R) One Receives European CE Mark Approval
Nov 30, 2011
|
11.1 KB
|
| |
SAN DIEGO, CA -- (MARKET WIRE) -- 11/30/11 --
Cytori's (NASDAQ: CYTX) Celution® One System, the next-generation device of the Company's Celution® platform, has been granted CE Mark approval. Celution® One is tailored specifically for the hospital as a platform device with potential life-critical applications across multiple spec...
|
|
|
Cytori Therapeutics Announces Participation in the 2011 Stem Cell Meeting on the Mesa's Investor and Partnering Forum
Nov 28, 2011
|
12.0 KB
|
| |
SAN DIEGO, CA -- (MARKET WIRE) -- 11/28/11 --
Cytori Therapeutics (NASDAQ: CYTX) will present at the 2011 Stem Cell Meeting on the Mesa's Investor and Partnering Forum on December 1. In addition, CEO Christopher Calhoun will participate on a regenerative medicine business panel also on December 1.
Cytori's presentation and panel ...
|
|
|
Cytori to Webcast Presentation at the Lazard Capital Markets 8th Annual Healthcare Conference on November 16, 2011
Nov 10, 2011
|
10.4 KB
|
| |
SAN DIEGO, CA -- (MARKET WIRE) -- 11/10/11 --
Cytori Therapeutics, Inc. (NASDAQ: CYTX) will webcast their corporate presentation at the Lazard Capital Markets 8th Annual Healthcare Conference at 9:30 AM (ET) on Wednesday, November 16, 2011 in New York.
The webcast may be accessed under "Webcasts" in the Investor Relations sectio...
|
|
|
Cytori Reports Third Quarter Business Update and Financial Results
Nov 3, 2011
|
24.0 KB
|
| |
SAN DIEGO, CA -- (MARKET WIRE) -- 11/03/11 --
Cytori Therapeutics (NASDAQ: CYTX) today is reporting its third quarter 2011 business update and financial results.
Product revenues for the third quarter of 2011 increased to $2.1 million, compared to $1.5 million in the third quarter of 2010. Gross profit increased to $1.2 million w...
|
|
| |
November 2011 Shareholder Letter
Nov 3, 2011
|
548.2 KB
|
|
Cytori to Webcast Third Quarter Financial Results November 3
Oct 26, 2011
|
10.2 KB
|
| |
SAN DIEGO, CA -- (MARKET WIRE) -- 10/26/11 --
Cytori Therapeutics (NASDAQ: CYTX) will provide a live webcast of its third quarter financial results and quarterly business update on Thursday, November 3, 2011 at 5:00 PM Eastern Time.
Prior to the webcast at approximately 4:05 PM Eastern Time on November 3, Cytori will issue its t...
|
|
|
Cytori & Apollo Hospitals Group of India Formalize Celution(R) Agreement
Sep 23, 2011
|
11.3 KB
|
| |
SAN DIEGO, CA -- (MARKET WIRE) -- 09/23/11 --
Cytori Therapeutics (NASDAQ: CYTX) has entered into a Celution® System agreement with Apollo Hospitals, one of Asia's largest private healthcare groups, to offer the technology initially at select cosmetic surgery centers in India.
"At Apollo Hospitals, we pride ourselves on int...
|
|
|
Cytori Amends and Expands Credit Facility Led by GE Capital, Healthcare Financial Services
Sep 12, 2011
|
11.2 KB
|
| |
SAN DIEGO, CA -- (MARKET WIRE) -- 09/12/11 --
Cytori Therapeutics (NASDAQ: CYTX) amended its loan facility with GE Capital, Healthcare Financial Services, Oxford Finance Corporation and Silicon Valley Bank by extending the maturity date from June 2013 to March 2015 and by increasing the funded facility from $20 million to $25 million. In addit...
|
|
|
CEO Chris Calhoun to Present Corporate Report at Cytori Annual Shareholder Meeting on August 16
Aug 15, 2011
|
10.2 KB
|
| |
SAN DIEGO, CA -- (MARKET WIRE) -- 08/15/11 --
Cytori Therapeutics (NASDAQ: CYTX) CEO Chris Calhoun will present a corporate report as part of the Annual Shareholder Meeting on August 16. Cytori will be hosting a webcast of the presentation and meeting on Tuesday, August 16 at 12 PM Eastern Time.
The webcast will be available bot...
|
|
|
Cytori Reports Second Quarter Results; Provides Commercial and Product Pipeline Update
Aug 9, 2011
|
197.3 KB
|
| |
SAN DIEGO, CA -- (MARKET WIRE) -- 08/09/11 --
Cytori Therapeutics, Inc. (NASDAQ: CYTX) provides a quarterly update on its development pipeline and reports financial results for the second quarter of 2011.
"Our focus is on advancing our cardiovascular disease product pipeline and growing our hospital-based soft tissue business," ...
|
|
|
August 2011 Shareholder Letter
Aug 9, 2011
|
192.7 KB
|
| |
Dear Shareholders,
Our corporate strategy is to focus on two therapeutics areas, cardiovascular disease and soft tissue repair, while simultaneously pursuing nearer-term sales opportunities. Thus far in 2011 and particularly the second quarter, we have made substantial progress on each front.
In cardiac, we have rep...
|
|
|
Cytori to Webcast Second Quarter Financial Results August 9 and Annual Shareholder Meeting on August 16
Aug 2, 2011
|
10.3 KB
|
| |
SAN DIEGO, CA -- (MARKET WIRE) -- 08/02/11 --
Cytori Therapeutics (NASDAQ: CYTX) will host a webcast to discuss its second quarter financial results and provide a commercial and development pipeline update on Tuesday, August 9, 2011 at 5:00 PM Eastern Time.
Prior to the webcast at approximately 4:05 PM Eastern Time on August 9, C...
|
|
|
Cytori Completes Equity Agreement; Funding to Support ADVANCE Clinical Trial & Other Corporate Initiatives
Jul 12, 2011
|
13.3 KB
|
| |
SAN DIEGO, CA -- (MARKET WIRE) -- 07/12/11 --
Cytori Therapeutics (NASDAQ: CYTX) entered into an equity purchase agreement with Seaside 88, LP ('Seaside'). As part of the agreement, Seaside completed the purchase of 1,326,262 common shares of Cytori at $4.52 per share for gross proceeds of $6,000,000 and committed to purchase an additional 5,00...
|
|
|
Cytori Reports Sustained Benefits at 18 Months in Cardiac Cell Therapy Heart Attack Trial
Jun 8, 2011
|
18.3 KB
|
| |
SAN DIEGO, CA -- (MARKET WIRE) -- 06/08/11 --
Cytori Therapeutics (NASDAQ: CYTX) is reporting 18 month outcomes from its APOLLO trial for Acute Myocardial Infarction (AMI). The results from the 14 patient, randomized, placebo-controlled, double-blind safety and feasibility trial in patients with ST-elevation AMI demonstrated the following:
...
|
|
|
Cytori Receives Cell-Enriched Fat Grafting Patent in Japan
Jun 2, 2011
|
11.9 KB
|
| |
SAN DIEGO, CA -- (MARKET WIRE) -- 06/02/11 --
Cytori Therapeutics (NASDAQ: CYTX) has received Japanese Patent No. 4722041 (the '041 patent) covering the preparation of adipose-derived stem and regenerative cell (ADRC) enriched fat grafts using any closed system, such as Cytori's Celution® System. The patent specifically protects the Compa...
|
|
|
NHS National Innovation Centre Identifies Celution(R) as Cost-Effective Innovative Technology for Partial Breast Reconstruction
May 31, 2011
|
15.4 KB
|
| |
ZUG, SWITZERLAND -- (MARKET WIRE) -- 05/31/11 --
Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that results from an economic analysis carried out by the UK NHS National Innovation Centre identified the Celution® System for breast reconstruction as an innovative technology that is bringing benefits to National Health Service (NH...
|
|
|
